Genmab's shares have doubled in three months following three successful Phase 3 cancer drug trials announced in October, including a promising head and neck cancer treatment, petosemtamab. The Danish biotech is shifting its business model to own more of its medicines, using royalty income from drugs like Darzalex to fund acquisitions and development. CEO Jan van de Winkel called this a "new era" as petosemtamab shows potential to become a multibillion-dollar drug. Genmab aims to expand its commercial reach and increase patient access while managing the risks of greater ownership and market challenges.
Genmab's recent success in cancer drug trials provides context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 03, 2026 14:11 WIB: Of 150 priced US health stocks, 60 rose and 87 fell. Notable movers include LQDA at USD 41.71 with a 7.43% drop and 100% sell order activity, WGS at USD 64.15 with a 7.11% drop and 100% buy order activity, and CLPT at USD 9.96 with a 6.83% drop and 92% sell order activity.
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...
